Clinical Trial Update: TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update for TSR-022 (anti-TIM-3) and TSR-042 (anti-PD-1) in adults with primary liver cancer; the study status is Active Not Recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Liver Cancer

Drugs mentioned

• TSR-022
• TSR-042 (dostarlimab)

Snippet

Sponsor: University of Hawaii | Conditions: Adult Primary Liver Cancer, Advanced Adult Primary Liver Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING